Stockscreener 앱 받기
6.76
2.89%
0.19
시장 영업 전:
6.64
-0.12
-1.78%
전일 마감가:
$6.57
열려 있는:
$6.58
하루 거래량:
369.17K
Relative Volume:
0.37
시가총액:
$450.44M
수익:
$80.00M
순이익/손실:
$-76.12M
주가수익비율:
-5.8962
EPS:
-1.1465
순현금흐름:
$-63.88M
1주 성능:
+14.38%
1개월 성능:
-13.78%
6개월 성능:
-40.28%
1년 성능:
+4.97%
1일 변동 폭
$6.455
$6.79
1주일 범위
$5.97
$6.79
52주 변동 폭
$5.88
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.76 | 437.78M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics (FULC) Steadies Near $6.57 as Biotech Sector Waits for CatalystSocial Momentum Signals - Newser
Fulcrum Therapeutics Q1 2026 Earnings: Narrowed Loss Exceeds Analyst ExpectationsEarnings Season Outlook - Newser
Fulcrum Therapeutics Q1 2026 Earnings: Narrowing Losses as Pipeline AdvancesPopular Market Picks - Newser
After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC) - Yahoo Finance Singapore
Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations - MSN
Fulcrum Therapeutics, Inc.Common Stock (NQ: FULC - FinancialContent
Nantahala Capital files: 3,050,040 shares (4.58%) in THERAPEUTICS, INC. (FULC) - Stock Titan
Fulcrum Therapeutics (FULC) amendment shows 5.25M-share, 7.9% position - Stock Titan
Fulcrum Therapeutics (FULC) Stock Analysis: Falls -6.05%, Watching $6.35 2026-05-15Trend Signals - newser.com
Fulcrum Therapeutics (FULC) Holds $$7.25 — Direction Awaited 2026-05-14Debt Free Stocks - Newser
Bank of America Securities Keeps Their Sell Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - MSN
Fulcrum Therapeutics (FULC.US) is scheduled to release its earnings report before the market opens on April 27. - Moomoo
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics (FULC) narrows Q1 loss 18% more than expected despite zero revenue; shares rise 2%.Growth Phase - newser.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Two new Fulcrum hires get 55,500 stock options at $7.02 a share - Stock Titan
What metric defines Fulcrum Therapeutics (FULC) success this quarter | Fulcrum Therapeutics Beats EPS ForecastTrending Stock Ideas - newser.com
FULC SEC FilingsFulcrum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
FULC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen - MarketBeat
Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price - Stock Titan
Fulcrum Therapeutics (NASDAQ: FULC) director files Form 3 with no shares owned - Stock Titan
[ARS] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay and auditor vote at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan
HC Wainwright Issues Optimistic Estimate for FULC Earnings - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
FULC Should I Buy - Intellectia AI
Fulcrum Therapeutics Shares Surge After Beating Q1 Earnings Estimates - HarianBasis.co
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $10 to $25 - Moomoo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownTime to Sell? - MarketBeat
Fulcrum Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Fulcrum Therapeutics, Inc. Q1 2026 Financial Results and Forward-Looking Statements Overview - Minichart
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulcrum Therapeutics Reports Positive Pociredir Data in Sickle Cell Disease, Strong Cash Position Through 2029 - Minichart
Value Trap or Opportunity? Fulcrum Therapeutics (FULC) Q1 2026 E - GuruFocus
Fulcrum Therapeutics (FULC) CFO Alan Musso to Retire This Year - GuruFocus
Fulcrum (FULC) Reports Financial Update and Clinical Progress - GuruFocus
Earnings call transcript: Fulcrum Therapeutics reports Q1 2026 earnings beat - Investing.com
Earnings call transcript: Fulcrum Therapeutics reports Q1 2026 earnings beat By Investing.com - Investing.com Australia
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Fulcrum Therapeutics, Inc. Announces Retirement of Alan Musso as Chief Financial Officer - marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism - ChartMill
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):